Abstract 4370053: Unique Insights into the Pathobiology of TNNI3 Cardiomyopathy using Novel Murine and Porcine Models of Disease

E Elizabeth Silver (University of California San Diego, San Diego, California, United States) B Betul Gunes (University of California San Diego, San Diego, California, United States) A Axel Fenwick (Johns Hopkins University, Baltimore, Maryland, United States) P Paul Bushway (University of California San Diego, La Jolla, California, United States) A Anthony Cammarato (Johns Hopkins University, Baltimore, Maryland, United States) S Sean Simpson (Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University) K Ki-Eun Park (RenOVAte Biosciences Inc, Reisterstown, Maryland, United States) J Jerel Waters (RenOVAte Biosciences Inc, Reisterstown, Maryland, United States) D Darla Tharp (University of Missouri, Columbia, Missouri, United States) B Bhanu Telugu (RenOVAte Biosciences Inc, Reisterstown, Maryland, United States) C Claire Geddes (Lexeo Therapeutics, New York, New York, United States) E Eric Adler (University of California, San Diego Medical Center, La Jolla)

Abstract

Background: Cardiac troponin I (cTnI, encoded by TNNI3 ) inhibits contraction by preventing actin-myosin interaction. Pathogenic TNNI3 variants can cause cardiomyopathy, but no targeted therapies exist. We identified a family with restrictive cardiomyopathy carrying the cTnI A157V variant. Previously, we generated a homozygous mouse model (cTnI A158V, murine equivalent) that showed impaired cardiac relaxation on invasive hemodynamics but had normal lifespan and no cardiac hypertrophy or fibrosis. Aims: It is known that murine models of cardiomyopathies often exhibit milder phenotypes than humans, limiting their translational utility. Hence, to better model human disease, we generated a homozygous cTnI A158V pig model using CRISPR-Cas9. We aimed to characterize phenotypic and molecular differences between the mouse and pig models to gain insight into disease mechanisms. Methods: Heart tissue was collected from wild-type (WT) and homozygous A158V mice (9-10 months) and from WT and homozygous A158V pigs (2 months). Bulk RNA sequencing (RNA-seq) was performed on RNA extracted from A158V pig hearts (n=5) and compared to publicly available data from age-matched WT pigs (n=10) supplemented by one in-house WT control. Protein lysates were analyzed by Western blot. Isolated myofibrils were measured using the fast solution switching method. Results: A158V pigs had 100% mortality by 2 months (n=7), with gross hypertrophy and fibrosis. Myofibril studies showed significant prolongation of the linear relaxation phase in both A158V pigs (p<0.01) and mice (p<0.01) compared to respective WTs, with no significant differences in active tension in both models. Both models showed reduced phosphorylation of cTnI at serine 23/24, reaching significance in pigs (p=0.046) but not in mice (p=0.064). Unsupervised clustering of bulk-RNAseq data separated A158V from WT, with genotype explaining 44% and 53% of transcriptional variation in mice and pigs, respectively. Gene set enrichment analysis revealed significant upregulation of inflammatory pathways in A158V pigs only. Conclusions: Both A158V mouse and pig models recapitulate impaired cardiac relaxation seen in affected patients as shown by myofibril studies. However, the pig model more closely mirrors the human phenotype, including early mortality, hypertrophy, and fibrosis. Inflammatory pathway upregulation was observed only in A158V pigs, suggesting that inflammation may play a role in the severity or progression of disease.

Article Details

Journal Circulation
Volume / Issue Vol. 152, Issue Suppl_3
Published November 04, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (12)

E

Elizabeth Silver

University of California San Diego, San Diego, California, United States

B

Betul Gunes

University of California San Diego, San Diego, California, United States

A

Axel Fenwick

Johns Hopkins University, Baltimore, Maryland, United States

P

Paul Bushway

University of California San Diego, La Jolla, California, United States

A

Anthony Cammarato

Johns Hopkins University, Baltimore, Maryland, United States

S

Sean Simpson

Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University

K

Ki-Eun Park

RenOVAte Biosciences Inc, Reisterstown, Maryland, United States

J

Jerel Waters

RenOVAte Biosciences Inc, Reisterstown, Maryland, United States

D

Darla Tharp

University of Missouri, Columbia, Missouri, United States

B

Bhanu Telugu

RenOVAte Biosciences Inc, Reisterstown, Maryland, United States

C

Claire Geddes

Lexeo Therapeutics, New York, New York, United States

E

Eric Adler

University of California, San Diego Medical Center, La Jolla